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Abstract
For HIV-infected patients, experiencing multiple traumas is associated with AIDS-related and all-cause mor-
tality, increased opportunistic infections, progression to AIDS, and decreased adherence to therapy. The impact
of intimate partner violence (IPV) on adherence and HIV outcomes is unknown. HIV-infected patients recruited
from a public HIV clinic participated in this observational cohort study (n = 251). Participants completed in-
terviews evaluating IPV and covariates. CD4 count < 200 (CD4 < 200), detectable HIV viral load (VL), and
engagement in care (‘‘no show rate’’ [NSR]) were the outcomes of interest. Medication adherence was not
measured. Univariate and multivariate regression analyses were performed with covariates included if p < 0.3 in
the univariate phase. Seventy-four percent of the participants were male, 55% Caucasian, and 52.2% self-
identified as ‘‘men who have sex with men.’’ IPV prevalence was 33.1% with no difference by gender or sexual
orientation. In univariate analysis, IPV exposure predicted having a CD4 < 200 ( p = 0.005) and a detectable VL
( p = 0.04) but trended toward significance with a high NSR ( p = 0.077). Being threatened by a partner was
associated with a CD4 < 200 ( p = 0.005), a detectable VL ( p = 0.011), and high NSR ( p = 0.019) in univariate
analysis. In multivariate analysis, IPV predicted having a CD4 < 200 ( p = 0.005) and detectable VL ( p = 0.035).
Being threatened by a partner predicted having a CD4 < 200 ( p = 0.020), a detectable VL ( p = 0.007), and a high
NSR ( p = 0.020). Our results suggest IPV impacts biologic outcomes and engagement in care for HIV-infected
patients. IPV alone predicts worse biologic outcomes, whereas the specific experience of being threatened by a
partner was associated with all three outcomes in univariate and multivariate analyses.
Introduction
Intimate partner violence (IPV) is common in the Uni-ted States and is known to affect health.1-6
Compared with people who have never experienced IPV,
victims of IPV have increased rates of depression, smoking,
drug and alcohol abuse, HIV-risk behaviors, sexually trans-
mitted infections, stroke, self-reported poor health, and an
increased risk of developing chronic diseases such as coronary
artery disease and hypertension. 1,2,4-7 Experience of IPV has
also been linked to increased symptom reporting, increased
use of the healthcare system, and poorer adherence to medical
therapy.4,6
IPV may also impact human physiology through biologic
mechanisms. In small studies, researchers have found signif-
icant differences in immune cell function, cytokine levels,
hemoglobin, mean corpuscular volume of red blood cells,
serum cortisol levels, and cell aging when comparing
IPV-exposed with unexposed women.8–11 Based on these
collective findings, we created a theoretical model of how IPV
exposure, worse HIV disease outcomes, and engagement in
care may interact (Fig. 1).
In the United States, *25% of women and 7.6% of men
experience IPV in their lifetimes.12 These numbers are star-
tling in their magnitude; however, they are thought to be
underestimates of the true prevalence. Limited data are
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available about IPV in males, both heterosexual and men who
have sex with men (MSM), and in transgender populations.
However, available estimates within populations of MSM
suggest that 22–32.4% of MSM experience IPV in their adult
lifetimes.13,14
Fewer investigations have evaluated IPV in the context of
an HIV-positive population. Estimates of IPV prevalence
range from 14% to 67% in HIV-positive women and up to
53.1% in a sample of HIV-positive men and women.15,16 Gi-
ven the high prevalence of IPV in HIV-positive populations, it
is important to define how IPV may affect HIV disease and
outcomes.15
This article reports the epidemiology of IPV and its asso-
ciations with disease outcomes and engagement in care in a
clinic that serves a predominantly rural HIV-positive popu-
lation at the University of Virginia (UVa). We hypothesized
that people living with HIV (PLWH) who experience IPV in
their adult lifetimes are more likely to have lower CD4 + cell
counts (CD4 count), higher frequency of detectable viral load
(VL), and poorer engagement in care. To our knowledge, this
is the first report of IPV as a specific category of trauma and its
relationship to engagement and outcomes for PLWH.
Methods
Sample and procedure
Between April 2010 and April 2011, we recruited 251 men
and women into a cross-sectional cohort study to evaluate the
relationships between IPV exposure and HIV outcomes. The
participants were recruited from the UVa Ryan White clinic
(RWC). The UVa RWC cares for > 650 patients from 52 coun-
ties in rural western Virginia (nearly 24,000 sqare miles), with
19 of these counties designated as ‘‘underserved’’ by the De-
partment of Health and Human Services. Some patients living
in far southwestern and northwestern Virginia travel 6 h to
medical appointments. Although the service area’s population
is 22% African-American, patients in the UVa RWC are 44%
African-American. Of these patients, 33% are female and,
among female patients, 50% are African-American. Poverty
and unemployment rates are 20% higher in the clinic’s catch-
ment area than average for Virginia, and the median income is
25% lower. People in this region are undereducated, with only
half of Caucasians and Hispanics and just over 25% of African-
Americans completing high school. Thirty-one percent of the
clinic patients have no health insurance.
The Principal Investigator (PI) selected and trained study
personnel to obtain informed consent and to administer the
interview tools. As part of the training, study staff observed
the PI while interviewing participants, and then were super-
vised during their first three enrollments. Prior to data col-
lection, the study protocol was approved by the UVa
Institutional Review Board.
Inclusion in the study required HIV seropositivity, age
‡ 18, and the ability to speak and comprehend English. Pa-
tients were ineligible to participate if these criteria were not
met or if they were currently incarcerated, or acutely ill and
in need of urgent medical attention. Potential participants
were approached while alone and in a private setting. Po-
tential participants were not approached if in the company of
another individual (such as a partner) in order to protect
confidentiality and to minimize risk should the partner be a
perpetrator of IPV. Written informed consent was obtained
prior to the interview, which included descriptions of the
following: study procedures (e.g., structured interview with
the interviewer using computers to enter responses), subject
areas and types of questions in the interview, ability of the
participant to decline answering any question, reimburse-
ment for participation ($5.00 gift card to retail outlet), and
available resources should the participant need support or
further counseling. Structured interviews were administered
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FIG. 1. Theoretical model of how IPV
may impact HIV-related outcomes.
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in a private setting using electronic forms created in Micro-
soft InfoPath (Microsoft Corporation, 2007). This format al-
lowed immediate, real-time upload of data into a Microsoft
Access database (Microsoft Corp, 2007), thereby decreasing
risks of input errors. Following the interview, all participants
were offered counseling, IPV victim resource information,
and further referrals, if appropriate. All participants were
also asked if they wanted any information from the inter-
view shared with their providers and social workers, which
was done if they desired.
Measures
Based on our theoretical model of how IPV could associate
with HIV outcomes, we also assessed other key variables
including: depression, socioeconomic status (SES), post-
traumatic stress disorder (PTSD), substance abuse, and life-
time stressors (Fig. 1).
IPV, traumatic events, and PTSD. We used the Women’s
Experiences with Battering (WEB) to estimate the adult life-
time prevalence of IPV exposure in the HIV clinic population
and to identify the exposed and unexposed subjects. The WEB
consists of 10 items derived from battered women focus group
descriptions of their IPV experiences. The items address a
participant’s loss of power and control (e.g., ‘‘My partner
makes me feel like I have no control over my life, no power,
no protection.’’) and use a Likert-type scale for degree of
agreement. Based on sensitivity and specificity analysis
performed by the instrument designers, a score of at least 20
constitutes a positive test for IPV (94.6% sensitivity and
96.1% specificity).17
For further characterization of the participants’ experience of
IPV, we used the Severity of Violence Against Women/Men
Scales (SVAW). The SVAW evaluates the frequency of specific
IPV behaviors in three dimensions: threat, violence, and sexual
aggression. Items address discrete behaviors (e.g., ‘‘How often
has your partner threatened to hurt you? How often has your
partner threatened to kill you?’’) and their frequency of oc-
currence during the last 12 months of a participant’s most re-
cent relationship. Chronbach’s a for men and women were
equally high (a = 0.95). Because all three subscales of this
measure demonstrated non-normality of distribution using a
visual inspection as well as a high skewness ( > 1.6), the final
subscale score was converted to a binary categorical measure of
positive or negative.18,19 Language used in all questions was
gender neutral in order to include men, women, homosexual,
and heterosexual subjects. We did not collect data on the spe-
cific timing of abuse.
In order to assess cumulative lifetime stressors, we used the
Life Stressor Checklist (LSC), a 30 item tool that includes
queries about episodes of violence as well as other nonviolent
events (e.g., illness, natural disaster, incarceration).20 This tool
is scored both for number of life stressors as well as a
weighted score for the participant’s subjective experience of
stress. PTSD was assessed using the PTSD Civilian Checklist
(PCL), a 17 item tool derived from the PTSD screen used for
combat veterans. 21
Psychological covariates. The Center for Epidemiologic
Studies Depression scale (CESD) is a 20 item assessment
using validated questions for depression. Scores are calcu-
lated from points per item, with higher points given for
higher frequency of depressive symptoms.22 The Addiction
Severity Index (ASI) is a multifaceted tool designed to assess
patients entering care for substance abuse. In its entirety, it
evaluates seven domains of life: medical, employment and
social support, drug and alcohol use, legal history, family
history, family and social relationships, and psychiatric
history. For the purposes of our study, we used only the
section addressing substance use, and calculated the devel-
oper-recommended composite scores to assess relative se-
verity of alcohol and drug use.23
Sociodemographic covariates. Age, sex, race, education
level, sexual orientation, and insurance status were recorded
from participant self-report. SES was determined by UVa pay
scale data in the participant’s medical record. UVa subsidizes
healthcare for patients with low incomes. The institution
categorizes individuals into six groups based on documented
income and assets. Each group pays a different percentage of
their medical costs ranging from 0 to 100%. For analysis, we
evaluated the following categories: low SES (no co-pay for the
patient), middle SES (5–70% co-pay for the patient), and high
SES (100% co-pay for the patient).
Outcomes. The primary outcome variables were CD4
count, HIV VL, and engagement in care, defined as clinic ‘‘no
show rate’’ (NSR). Laboratory results and visit attendance
were abstracted from the medical record. NSR was calculated
as the number of medical visits not attended (nor canceled or
rescheduled by the participant) divided by the total number of
scheduled visits during an 8–12 month period. These vari-
ables were all highly non-normally distributed and are typi-
cally used in binary format for clinical application (e.g.,
CD4 < 200 or CD4 ‡ 200, HIV VL detectable or undetectable).
NSR was classified into two categories (‘‘High NSR, ‡ 33%
missed visits’’ and ‘‘Low NSR, < 33% missed visits’’) based on
the visualized distribution of participants.
Statistical analysis
IBM SPSS software (version 19.0) was used for all statis-
tical analyses. Patient characteristics were reported as fre-
quency with percentage for categorical and mean with – SD
for continuous data. Pearson’s v2 test for goodness of fit
statistic was applied to univariate analyses of categorical
predictors of each of three outcomes including CD4 < 200,
detectable VL and NSR. Odds ratios (OR) with 95% confi-
dence intervals (CI) were reported for 2 · 2 dichotomous
comparisons. The Student’s paired sample t test was applied
to univariate analyses of continuous predictors of each out-
come. Variables were included in multivariate logistic re-
gression models if they met a conservatively set p £ 0.30




A total of 251 patients were enrolled between April 13,
2010 and April 28, 2011. Although 87% of patients ap-
proached were willing to participate, the final participation
rate (defined as all those completing study instruments
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divided by all those approached) from June 10, 2010 until
April 28, 2011 was 57% (data on response were not collected
prior to June 2010). Patients who expressed interest in the
study but deferred participation cited time and illness as the
primary reasons for postponing. Demographic characteris-
tics of the sample are described in Table 1. The sample was
mostly male (74.5%), between the ages of 41 and 45, and
predominantly white (55%). Thirty-nine percent of the par-
ticipants were African-American. Of the male participants,
70% (n = 131) self-identified as MSM (52.2% of total sample).
The demographics of our sample matched the overall profile
of the clinic population where 69% of the patients are male,
49% are between the ages of 49 and 64, 43% are black/Af-
rican American, and 45% of patients in clinic self identify as
MSM. Eighty-three (33.1%) participants reported experi-
encing IPV during their adult lifetimes, as defined by a score
‡ 20 on the WEB. Pearson’s v2 analysis showed no associa-
tion between IPV and sex or sexual orientation.
In addition to assessing gross IPV prevalence, we also
measured experience of threats by a partner (partner threat)
using the SVAW. Sixty-nine percent (n = 172) of participants
had experienced partner threat during the last 12 months of
the most recent relationship (Table 1). Separate models were
used for IPV exposure (defined as a positive WEB) and part-
ner threat.
Table 1. Participant Demographics
and Clinical Characteristics






















Native American 2 (0.8)
Unknown 1 (0.4)











Completed 12th grade 210 (83.7)
Socioeconomic status
(SES)a (n[%])
Low SES 105 (41.8)
Mid-range SES 35 (13.9)













Clinic no show rate
(NSR) (n[%])
< 33% 214 (85.3)
‡ 33% 37 (14.7)






(defined by WEB) (n[%])
83 (33.1)
Table 1. (Continued)
Characteristic Overall sample (n = 251)
Partner threat in




screena (n = 246)
116 (46.2)
Positive PTSD screena (n = 248) 57 (22.7)
Lifetime traumatic
experiencesa








in past 30 daysa
(n[%]) (n = 245)
61 (24.3)
Participants using drugs
in past 30 daysa.b
(n[%]) (n = 246)
67 (26.7)
Participants with a history





aData for some variables were not available for the entire group.
bIncludes: cocaine, amphetamines, cannabis, and inhalants.
MSM, men who have sex with men; HSM, heterosexual males;
HSF, heterosexual women; WSW, women who have sex with
women; IQR, interquartile range; IPV, intimate partner violence;
WEB, womens’ experiences with battering; SVAW, Severity of
Violence Against Women/Men Scales; PTSD, post-traumatic stress
disorder; IVDU, intravenous drug use.






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































IPV and HIV disease outcomes
The median CD4 count for this sample was 551 cells/lL
and 46.4% (n = 117) of the participants had an undetectable VL
(Table 1). These figures mirror the larger clinic population
from which the sample was drawn; in comparison, the me-
dian CD4 count for the entire clinic is 510.5 cells/lL and 53%
of patients have an undetectable VL. Univariate analyses were
used to assess the predictive value of variables with respect to
having a CD4 < 200 (Table 2). In multivariate analysis, IPV
exposure and male sex were independent, significant pre-
dictors of having a CD4 < 200 (Table 3). These variables ex-
plained 12% (Nagelkerke R2) of the variance associated with
having a CD4 < 200.
Partner threat also predicted having a CD4 < 200 ( p = 0.005;
OR 10.13 [95% CI 1.34–76.91]) in univariate and multivariate
analysis ( p = 0.020; relative risk [RR] 11.67 [95% CI 1.47–92.49]).
The only other significant predictor of having a CD4 < 200 in
this model was race other than white or African-American
(Table 3). These variables explained 17.8% (Nagelkerke R2) of
the variance associated with having a CD4 < 200.
Univariate analysis was also used to assess the predictive
value of variables with respect to having a detectable HIV VL
(Table 2). Age, race, IPV exposure, and alcohol abuse were all
associated with having a detectable VL. Multivariate analysis
identified IPV exposure, younger age, increased lifetime
stressors, and alcohol abuse as independent predictors of
having a detectable VL, whereas race was no longer signifi-
cant (Table 3). Conversely, a positive PTSD screen was in-
versely associated with having a detectable VL (Table 3).
These variables explained 14% (Nagelkerke R2) of the vari-
ance associated with having a detectable VL. Similarly, part-
ner threat also predicted having a detectable VL ( p = 0.011; OR
2.03 [95% CI 1.16–3.53]) in univariate analysis. In multivariate
analysis, partner threat, age, race other than white or African-
American, and alcohol abuse, were all independent, signifi-
cant predictors of having a detectable VL (Table 4). A positive
PTSD screen and midrange SES were inversely related to
having a detectable VL (Table 4). These variables explained
16.8% (Nagelkerke R2) of the variance associated with having
a detectable VL.
IPV and engagement in care
In univariate analysis (Table 2), the average NSR was sig-
nificantly higher for people threatened by their partners in the
last 12 months of their most recent relationship ( p = 0.019). For
the entire sample, the risk of an NSR > 33% trended toward
significance in participants with a history of IPV in univariate
analysis ( p = 0.077). Univariate analysis for men only showed
a significant relationship between IPV exposure and having a
high NSR ( p = 0.045; OR 2.34 (95% CI 1.03–5.31)). Partner
threat emerged as the only significant predictor of having a
high NSR in multivariate analysis ( p = 0.020; RR 3.21 [95% CI
1.20–8.60]).
Discussion
In our full cohort, IPV, defined by the WEB instrument,
negatively impacts important HIV disease markers for PLWH
and trends toward significant impairment of engagement in
care. The risk of poor engagement in care is particularly high
in men who have experienced abuse. Both the experience of
IPV and threats from a partner predict having a CD4 < 200 and
a detectable VL. These relationships remained, independent
of age, race, education, sexual orientation, SES, insurance
status, PTSD, depression, cumulative life stressors, and sub-
stance abuse. These results augment previously published
research showing strong relationships between cumulative
trauma exposure (not exclusive to IPV) and poor health out-
comes.1,2,4,5,10,24,25 Small foundational studies suggest the bi-
ologic plausibility of this finding by showing that people who
experience IPV may have altered cortisol responses and in-
appropriate T-cell activation as well as early cell senes-
cence.8,9,11 Furthermore, increased lifetime traumatic
experiences and stress are associated with worse medication
adherence, a factor that clearly impacts the biologic outcomes
of PLWH.26,27 Interestingly, PTSD appears to decrease the risk
of having a detectable VL, which could reflect the known
association between PTSD and increased healthcare utiliza-
tion.28–30 This finding could also reflect the previously de-
scribed association between receiving treatment for HIV and
development of post-traumatic stress symptoms.31
CD4 count and HIV VL have traditionally been the mea-
sures by which we predict HIV outcomes. However, en-
gagement in care is emerging as a significant factor in the
health of PLWH. Engagement has been described as a con-
tinuum of processes through which patients move: from ig-
norance of the HIV infection, to diagnosis but being out of
care, then linkage to care, and finally to being fully engaged
and retained in HIV care.32 Visit attendance and adherence to
antiretroviral therapy are critical elements if patients are to
reach and remain fully engaged in care. These measures are
Table 3. Multivariate Results for IPV Model
CD4 < 200 Detectable viral load High NSR ( > 33%)
Variable RR(95% CI) p Value RR (95% CI) p Value RR (95% CI) p Value
Intimate partner violence (WEB) 3.97 (1.51–10.42) 0.005 1.92 (1.05–3.54) 0.035 NS
Men 4.9 (1.18–20.5) 0.028 NS NS
MSM 0.35 (0.12–1.00) 0.052 NS NS
Age NS 0.51 (0.30–0.88) 0.015 NS
Positive PTSD screen NS 0.31 (0.15–0.67) 0.003 NS
Overall life stressor score NS 1.07 (1.00–1.14) 0.040 1.08 (1.01–1.16) 0.035
Severity of alcohol use NS 19.40 (1.60–234.95) 0.020 NS
IPV, intimate partner violence; NSR, ‘‘no show’’ (at appointments) rate; RR, relative risk; WEB, womens’ experiences with battering; MSM,
men who have sex with men; PTSD, post-traumatic stress disorder.
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often used as surrogate markers of engagement, given the
documented benefits of consistent medication use and ap-
pointment attendance on reducing VL, raising the CD4 count,
and, ultimately, survival.26,33 Exposure to higher levels of
lifetime trauma (including, but not limited to, physical and
sexual abuse) is associated with nonadherence, a factor that
could contribute to worse outcomes in an abused popula-
tion.26,27 Recent analysis by Siemieniuk et al. suggests that
PLWH who specifically experience abuse may be more likely
to miss clinic visits.14
Whereas we show a trend toward a significant relationship
between WEB-defined IPV and a higher NSR, our results in-
dicate that the specific experience of being threatened by a
partner significantly predicts having poorer engagement in
care in our population. For individuals currently abused (in-
cluding by threats), possible connections between IPV and not
attending clinic visits include: resource deprivation (e.g.,
money or transportation) by one partner over another, fear of
rejection or violent retribution by a partner in response to
disclosure of HIV seropositivity, overall poor health, denial
when asymptomatic, or an unidentified interaction of factors
remaining to be determined.34,35 For people with both a cur-
rent or past history of IPV, the perceived loss of power and
control may be so deeply ingrained that distrust and self-
isolation pervade.5
Limitations of our study include: a relatively small sample
size, single study site design, and a low proportion of females.
Additionally, we did not measure medication adherence as a
component of engagement in care for our cohort. Other lim-
itations of our study relate to the assessment tools used to
detect and rate the severity of IPV. Neither the WEB nor the
SVAW has been validated in MSM and the majority of our
participants self-identify in this demographic. These instru-
ments may under- or overestimate the IPV prevalence of our
sample because the dynamics in a same-sex relationship may
not be captured by the items. There is also the possibility of
selection bias in either direction; the patients most likely to
participate may be abused and more likely to seek contact
with the healthcare environment. Conversely, the patients
who declined to participate may have done so because they
are abused and are fearful of disclosure. Additionally, we did
not screen patients who attended their appointments with a
partner or family member, which may inherently exclude
people most at risk for being controlled or abused by others.
Our results add to the limited body of literature investigating
the prevalence of IPV in males, specifically MSM who are also
HIV positive. They highlight the need for greater resources and
services for men who experience IPV. Additional research is
needed to validate existing IPV screening tools for MSM as well
as longitudinal studies to measure how IPV exposure prospec-
tively impacts HIV outcomes and engagement.
There is currently a paucity of information about the HIV
epidemic in rural HIV-positive populations in developed
nations. Our work contributes to a greater understanding of
epidemiology and disease outcomes in the non-urban south-
east United States. Recent work by Meditz et al. suggests
worse clinical outcomes for PLWH in the southern United
States, particularly nonwhites and women, and emphasizes
the need to improve our understanding of this population’s
differential HIV courses in order to better serve them.36 IPV
appears to be an important determinant of HIV outcomes in
this population, and should be identified through routine
screening of patients in HIV clinics.
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